IDH1 and acute myeloid leukemia: After three to four decades of a stagnant therapeutic landscape, we finally saw a series of new drug approvals in AML since 2017 (see recent reviews) [9,10]: FLT3 (midostaurin and gilteritinib) and IDH inhibitors (ivosidenib and enasidenib), VEN, glasdegib, gemtuzumab ozogamicin, CPX-351, and oral azacitidine (AZA).